Most of my research has involved costing or cost-effectiveness analyses to inform interventions for infectious diseases in the Asia-Pacific region. Some of these include mass drug administration for scabies, public health measures for COVID-19, molecular testing for malaria and arboviruses, and pneumococcal conjugate vaccines. I am mailny interested in improving methods in economic evaluation. I am also keen on assessing multicomponent interventions, conducting evaluations using real-world data, and creating user- friendly decision models.
Journal articles
-
Carvalho N, Jayasundara P, Abd Rahim KNK, Akpan E, Devine A, Hughes A, et al. “Epidemiologic and economic modelling of COVID-19 public health interventions in Malaysia during 2021 and 2022.” Melbourne Health Economics 2024. doi:
10.26188/28015307.v1 -
Akpan E, Thean LJ, Baskota R, Mani J, Mow M, Sahukhan A, et al. “Costs of primary healthcare presentations and hospital admissions for scabies and related skin infections in Fiji, 2018-2019.” PLOS Global Public Health. 2024; 4(10):e0003706. doi:
10.1371/journal.pgph.0003706 -
Le TP, Conway E, Akpan E, Abell I, Abraham P, Baker CM, et al. “Cost-effective boosting allocations in the post-Omicron era of COVID-19 management.” medRxiv. 2022; 2023. doi:
10.1101/2023.11.14.23298536 -
Akpan E, Hossain SJ, Devine A, Braat S, Hasan MI, Tipu SMMU, et al. “Cost-effectiveness of universal iron supplementation and iron-containing micronutrient powders for anemia among young children in rural Bangladesh.” American Journal of Clinical Nutrition. 2022; 116(5):123–140. doi:
10.1093/ajcn/nqac225